| Gene symbol | GPC3 | Synonyms | DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB, SGBS, SGBS1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq26.2 | dbXrefs | |
| Description | glypican 3 | ||||
| GTO ID | GTC3622 |
| Trial ID | NCT06084884 |
| Disease | Hepatocellular Carcinoma |
| Altered gene | GPC3 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | AZD5851 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA |
| Year | 2023 |
| Country | Korea, Republic of|United States |
| Company sponsor | AstraZeneca |
| Other ID(s) | D7670C00001 |
| Cohort 1 | |||||||||
|
|||||||||